Media advisory - ATRIPLA(TM) receives reimbursement approval in Quebec

    The First Once-Daily Single Tablet Regimen for HIV Can Help Simplify

    MISSISSAUGA, ON and MONTREAL, June 2 /CNW Telbec/ - Bristol-Myers Squibb
Canada and Gilead Sciences, Inc. (Nasdaq:   GILD) announced today that
ATRIPLA(TM) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil
fumarate 300 mg), the only once-daily, single-tablet HIV regimen in Canada,
has received approval from the Quebec Minister of Health following a
recommendation from the Conseil du médicament du Québec. Effective immediately
ATRIPLA will be fully listed on Liste de médicaments du régime général
(general formulary) and Liste de médicaments-établissements (institutional
formulary). ATRIPLA was approved by Health Canada in October 2007 for use
alone as a complete regimen or in combination with other antiretroviral agents
for the treatment of HIV-1 infection in adults.
    ATRIPLA was developed through a joint venture partnership between
Bristol-Myers Squibb Company and Gilead Sciences. ATRIPLA combines SUSTIVA(R)
(efavirenz), manufactured by Bristol-Myers Squibb Company, and Truvada-
(emtricitabine/tenofovir disoproxil fumarate), manufactured by Gilead
Sciences. Truvada itself is a fixed-dose product that contains two of Gilead's
anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R)
(emtricitabine), in a single once-daily tablet for use as part of combination
therapy. All three medicines work by blocking reverse transcriptase, an enzyme
necessary for HIV replication.
    ATRIPLA will allow suitable HIV patients in Québec to take a complete
treatment regimen in one pill, once daily, which is a significant advance over
the complex dosing schedules and dietary restrictions required by some HIV
    ATRIPLA was approved by the U.S. Food and Drug Administration in July
2006 and has since become the most prescribed treatment regimen for patients
starting HIV therapy in the United States. In Canada, approximately
61,000 people are living with HIV, and roughly 2,500 new HIV diagnoses are
reported each year. Approximately 27 percent of those with HIV are unaware of
their infection.
    It is important for patients to be aware that anti-HIV medicines do not
cure HIV infection or AIDS and have not been shown to reduce the risk of
transmitting HIV to others.

    All HIV medicines can have serious side effects. Patients should consult
               a doctor before initiating or changing therapy.

         The Canadian product monograph for ATRIPLA is available at
         The Canadian product monograph for SUSTIVA is available at
     The Canadian product monographs for Truvada, Viread and Emtriva are
                         available at

For further information:

For further information: Marc Osborne, Bristol-Myers Squibb Canada,
(514) 333-2463,; Meredith Fuller, Quarry Integrated
Communications, (519) 570-2020 ext. 2443,

Organization Profile

Clinique médicale l'Actuel

More on this organization

Bristol-Myers Squibb Company

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890